85 results
8-K/A
EX-99.1
NKTX
Nkarta, Inc.
15 Aug 24
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
7:12pm
is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting
8-K
EX-99.1
NKTX
Nkarta, Inc.
13 Aug 24
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
4:05pm
is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting
8-K
EX-99.1
NKTX
Nkarta, Inc.
16 Jul 24
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
6:30am
engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access
8-K
EX-99.1
NKTX
Nkarta, Inc.
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more
8-K
EX-99.1
ji72t9ll
13 Jun 24
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
4:22pm
8-K
EX-99.1
oi6m0fm2557ztqov
9 May 24
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4:04pm
8-K
EX-1.1
2bgbt2qj
28 Mar 24
Other Events
4:08pm
424B5
araur4xrp8y
25 Mar 24
Prospectus supplement for primary offering
8:15pm
8-K
EX-99.1
17rgpsn ym1
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
EX-99.1
g33ktc6
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
EX-99.1
g92dz
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
EX-99.1
o95sdsgw
16 Oct 23
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
4:07pm
8-K
EX-99.1
hcukwq
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am